Abstract

Blood-tumor barrier (BTB) limits the delivery of chemotherapeutic agent to brain tumor tissues. Long non-coding RNAs (lncRNAs) have been shown to play critical regulatory roles in various biologic processes of tumors. However, the role of lncRNAs in BTB permeability is unclear. LncRNA TUG1 (taurine upregulated gene 1) was highly expressed in glioma vascular endothelial cells from glioma tissues. It also upregulated in glioma co-cultured endothelial cells (GEC) from BTB model in vitro. Knockdown of TUG1 increased BTB permeability, and meanwhile down-regulated the expression of the tight junction proteins ZO-1, occludin, and claudin-5. Both bioinformatics and luciferase reporter assays demonstrated that TUG1 influenced BTB permeability via binding to miR-144. Furthermore, Knockdown of TUG1 also down-regulated Heat shock transcription factor 2 (HSF2), a transcription factor of the heat shock transcription factor family, which was defined as a direct and functional downstream target of miR-144. HSF2 up-regulated the promoter activities and interacted with the promoters of ZO-1, occludin, and claudin-5 in GECs. In conclusion, our results indicate that knockdown of TUG1 increased BTB permeability via binding to miR-144 and then reducing EC tight junction protein expression by targeting HSF2. Thus, TUG1 may represent a useful future therapeutic target for enhancing BTB permeability.

Highlights

  • Glioblastoma multiforme (GBM) is one of the most lethal primary malignant brain tumors

  • Quantitative real-time PCR analysis was applied to detect the expression of Long non-coding RNAs (lncRNAs) Taurine upregulated gene 1 (TUG1) in glioma vascular

  • In Situ Hybridizations (ISH) analysis was applied to detect the expression of lncRNA TUG1 in low and high grade glioma tissues as well as in normal brain tissues (Figure 1C)

Read more

Summary

Introduction

Glioblastoma multiforme (GBM) is one of the most lethal primary malignant brain tumors. The existence of blood-tumor barrier (BTB) contributes to the failure of conventional chemotherapy by restricting sufficient drug molecules delivery to tumor tissues [1,2,3]. Selectively open the BTB without effecting normal blood-brain barrier (BBB) is considered promising future therapeutic strategies for effective chemotherapy of glioma. Drugs cross the BTB by two pathways: paracellular or transcellular [4]. The transcellular pathway is the main route of absorption for chemotherapy drug molecules [5, 6]. The paracellular pathway is composed of the tight junction complex (TJs) including zonula occludens (ZOs), transmembrane proteins of occludin and claudins, et al [7]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call